- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Immune Antibody Preparation Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- How much do you know about ADC drug development?
- Novel Cancer Therapeutic Strategy: Development of Bispecific Antibody-Drug Conjugates
- Nveiling the Molecular and Immunological Drivers of Antibody-Drug Conjugates (ADCs) in Cancer Treatment
- A PBD Dimer-Containing Antibody-Drug Conjugate (KK2845) Targeting TIM-3-Expressing AML
- A Novel Approach for Cancer Therapy - Modulating TCR Complex Recruitment to the T Cell Antigen Coupler (TAC) Enhances TAC-T Cell Function
- Development of Therapeutic Monoclonal Antibodies for Disease Treatment
- Common Problems and Solutions of Prokaryotic Expression of Recombinant Protein
- Neutralizing Monoclonal Antibody Development Service FAQ
- A Brief Discussion on Prokaryotic Expression of Recombinant Antibodies
- Common Problems and Solutions for Recombinant Antibody Yeast Expression Experiments
Special topic on antibody modification
- Eukaryotic System-Based Targeted Drug Discovery Platform: Yeast Display Technology
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
- Overview of Yeast Two Hybrid System Principle and Application
- Introduction to Yeast Display Antibody Screening Technology
- Overview of Yeast Display Technology
- Overview of Yeast Two Hybrid Technology
- Yeast Display Platform for Rapid Nanobody Discovery
- What is the essential difference between antibody phage display and yeast display?
Yeast Display Technology Special Topic
- Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?
- Yeast Hybrid Library Construction: Smart Technology
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
- Antibody Affinity Test EC50
- Antibody Full Length Sequencing
Antibody Detection Service Topic
- How much do you know about IgG, Fab, scFv, and VHH?
- Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model
- Non-Invasive In Vivo Monitoring of PROTAC-Mediated Protein Degradation Using an Environment-Sensitive Reporter
- How do you know Phage Display Peptide Library?
- Phage Display Peptide Library
- Phage Display Antibody Library Technology
- Efficient Screening Methods and Research Progress of Anti-tumor Polypeptides
- Molecular Screening and Application of Targeted Peptides
- Screening Strategies for Cyclic Peptide Drugs
- Construction Method of Random Peptide Library
Special Topic on Phage Display Technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Molecular Biology Service Topics
-
Product Center
- Contact Us
Product Center
About US
-
Phone
400-168-8285 -
Email
info@tekbiotech.com -
Address
Building A5, International Enterprise Community, Wuqing, Tianjin
Inquiry and ordering
Product Center
TekBiotech understands your critical needs in drug discovery and quality control. Your work demands rigorous consistency between batches, superior biological activity, and ultra-low endotoxin levels—and we are built to deliver. We have developed a compreh
Recombinant AntibodyAnti-CD309重组抗体|科研级 Alacizumab(阿拉赛珠单抗 )
Datasheet
- TKYR1150
- 科研级 Alacizumab(阿拉赛珠单抗 ), Anti-CD309 Recombinant Antibody, Research Grade Alacizumab
- Alacizumab
- 1mg, 5mg
- 934216-54-3
Anti-CD262重组抗体|科研级 Tigatuzumab ( 替加组单抗 )
Datasheet
- TKYR1151
- 科研级 Tigatuzumab ( 替加组单抗 ), Anti-CD262 Recombinant Antibody, Research Grade Tigatuzumab
- Tigatuzumab
- 1mg, 5mg
- 918127-53-4
Anti-CD3E重组抗体|科研级 Otelixizumab ( 奥昔组单抗 )
Datasheet
- TKYR1152
- 科研级 Otelixizumab ( 奥昔组单抗 ), Anti-CD3E Recombinant Antibody, Research Grade Otelixizumab
- Otelixizumab
- 1mg, 5mg
- 881191-44-2
Anti-CD326重组抗体|科研级 Citatuzumab( 西他土珠 )
Datasheet
- TKYR1153
- 科研级 Citatuzumab( 西他土珠 ), Anti-CD326 Recombinant Antibody, Research Grade Citatuzumab
- Citatuzumab
- 1mg, 5mg
- 945228-49-9
Anti-CD326重组抗体|科研级 Oportuzumab( 莫妥组单抗 )
Datasheet
- TKYR1154
- 科研级 Oportuzumab( 莫妥组单抗 ), Anti-CD326 Recombinant Antibody, Research Grade Oportuzumab
- Oportuzumab
- 1mg, 5mg
- 945228-48-8
Anti-CD20重组抗体|科研级 Obinutuzumab ( 阿托珠单抗 )
Datasheet
- TKYR1155
- 科研级 Obinutuzumab ( 阿托珠单抗 ), Anti-CD20 Recombinant Antibody, Research Grade Obinutuzumab
- Obinutuzumab
- 1mg, 5mg
- 949142-50-1
Anti-ITGAV & ITGB3重组抗体|科研级 Etaracizumab ( 埃达组单抗 )
Datasheet
- TKYR1156
- 科研级 Etaracizumab ( 埃达组单抗 ), Anti-ITGAV & ITGB3 Recombinant Antibody, Research Grade Etaracizumab
- Etaracizumab
- 1mg, 5mg
- 892553-42-3
Anti-CD4 D3 Domain重组抗体|科研级 Ibalizumab ( 伊巴组单抗 )
Datasheet
- TKYR1157
- 科研级 Ibalizumab ( 伊巴组单抗 ), Anti-CD4 D3 Domain Recombinant Antibody, Research Grade Ibalizumab
- Ibalizumab
- 1mg, 5mg
- 680188-33-4
Anti-Serotype IATS O12重组抗体|科研级 Panobacumab ( 帕巴库单抗 )
Datasheet
- TKYR1158
- 科研级 Panobacumab ( 帕巴库单抗 ), Anti-Serotype IATS O12 Recombinant Antibody, Research Grade Panobacumab
- Panobacumab
- 1mg, 5mg
- 885053-97-4
Anti-IL1B重组抗体|科研级 Canakinumab ( 卡那奴单抗 )
Datasheet
- TKYR1159
- 科研级 Canakinumab ( 卡那奴单抗 ), Anti-IL1B Recombinant Antibody, Research Grade Canakinumab
- Canakinumab
- 1mg, 5mg
- 914613-48-2
To experience the reliable service of Tekbiotech please subscribe:
-
Antibody Discovery
-
Antibody Production
-
Antibody Modification
Contact
- Phone：400-168-8285
- Email：info@tekbiotech.com
- Address：Building A5, International Enterprise Community, Wuqing, Tianjin
Follow us!
Technical Support
©2026Tekbiotech (Tianjin) Co., Ltd